Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer

FASEB Journal

Volumn 25, Issue 4, 2011, Pages 1198-1207

  Siddiqui, Imtiaz A ^a   Asim, Mohammad ^a,b   Hafeez, Bilal B ^a   Adhami, Vaqar M ^a   Tarapore, Rohinton S ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Li Ka Shing Centre   (United Kingdom)

Author keywords

Androgen antagonist; Androgen receptor signaling; Androgen regulated miRNA; Hormone refractory prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; EPIGALLOCATECHIN GALLATE; MICRORNA 21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TEA; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN RECEPTOR ANTAGONISTS; BINDING, COMPETITIVE; CATECHIN; COMPUTER SIMULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TEA; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

MUS;

EID: 79954572581     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-167924     Document Type: Article

References (57)

1. Weir, H. K., Thun, M. J., Hankey, B. F., Ries, L. A., Howe, H. L., Wingo, P. A., Jemal, A., Ward, E., Anderson, R. N., and Edwards, B. K. (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 95, 1276-1299 (Pubitemid 37160862)
2. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249
3. Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., and Greenberg, N. M. (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 120, 719-733 (Pubitemid 46175390)
4. Chodak, G. W., Kranc, D. M., Puy, L. A., Takeda, H., Johnson, K., and Chang, C. (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J. Urol. 147, 798-803
5. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H., and van der Kwast, T. H. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735-746 (Pubitemid 24172062)
6. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (Pubitemid 38524696)
7. Ricciardelli, C., Choong, C. S., Buchanan, G., Vivekanandan, S., Neufing, P., Stahl, J., Marshall, V. R., Horsfall, D. J., and Tilley, W. D. (2005) Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63, 19-28 (Pubitemid 40365387)
8. Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., and Sutherland, R. L. (2001) Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 61, 423-427 (Pubitemid 32128590)
9. Perry, J. E., Grossmann, M. E., and Tindall, D. J. (1996) Androgen regulation of gene expression. Prostate Suppl. 6, 79-81 (Pubitemid 26112293)
10. Young, C. Y., Andrews, P. E., Montgomery, B. T., and Tindall, D. J. (1992) Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31, 818-824
11. Isaacs, J. T. (2000) Apoptosis: translating theory to therapy for prostate cancer. J. Natl. Cancer Inst. 92, 1367-1369
12. Chen, S., Song, C. S., Lavrovsky, Y., Bi, B., Vellanoweth, R., Chatterjee, B., and Roy, A. K. (1998) Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol. Endocrinol. 12, 1558-1566 (Pubitemid 30663438)
13. Haag, P., Bektic, J., Bartsch, G., Klocker, H., and Eder, I. E. (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J. Steroid Biochem. Mol. Biol. 96, 251-258 (Pubitemid 41080506)
14. Liao, X., Tang, S., Thrasher, J. B., Griebling, T. L., and Li, B. (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther. 4, 505-515 (Pubitemid 40601831)
15. McLarty, J., Bigelow, R. L., Smith, M., Elmajian, D., Ankem, M., and Cardelli, J. A. (2009) Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. (Phila.) 2, 673-682
16. Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., and Corti, A. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 66, 1234-1240 (Pubitemid 43165995)
17. Adhami, V. M., Malik, A., Zaman, N., Sarfaraz, S., Siddiqui, I. A., Syed, D. N., Afaq, F., Pasha, F. S., Saleem, M., and Mukhtar, H. (2007) Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 13, 1611-1619 (Pubitemid 46450454)
18. Siddiqui, I. A., Zaman, N., Aziz, M. H., Reagan-Shaw, S. R., Sarfaraz, S., Adhami, V. M., Ahmad, N., Raisuddin, S., and Mukhtar, H. (2006) Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 27, 833-839
19. Chuu, C. P., Chen, R. Y., Kokontis, J. M., Hiipakka, R. A., and Liao, S. (2009) Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 275, 86-92
20. Morrissey, C., Brown, M., O'Sullivan, J., Weathered, N., Watson, R. W., and Tenniswood, M. (2007) Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. Int. J. Urol. 14, 545-551 (Pubitemid 46985545)
21. Naftalin, R. J., Afzal, I., Cunningham, P., Halai, M., Ross, C., Salleh, N., and Milligan, S. R. (2003) Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. Br. J. Pharmacol. 140, 487-499 (Pubitemid 37330493)
22. Ren, F., Zhang, S., Mitchell, S. H., Butler, R., and Young, C. Y. (2000) Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19, 1924-1932 (Pubitemid 30219035)
23. Siddiqui, I. A., Malik, A., Adhami, V. M., Asim, M., Hafeez, B. B., Sarfaraz, S., and Mukhtar, H. (2008) Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27, 2055-2063 (Pubitemid 351442738)
24. Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., and Mukhtar, H. (2008) Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 27, 3596-3604 (Pubitemid 351793796)
25. Ozers, M. S., Marks, B. D., Gowda, K., Kupcho, K. R., Ervin, K. M., De Rosier, T., Qadir, N., Eliason, H. C., Riddle, S. M., and Shekhani, M. S. (2007) The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46, 683-695 (Pubitemid 46133586)
26. Siddiqui, I. A., Shukla, Y., Adhami, V. M., Sarfaraz, S., Asim, M., Hafeez, B. B., and Mukhtar, H. (2008) Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm. Res. 25, 2135-2142
27. Cantin, L., Faucher, F., Couture, J. F., de Jesus-Tran, K. P., Legrand, P., Ciobanu, L. C., Frechette, Y., Labrecque, R., Singh, S. M., Labrie, F., and Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J. Biol. Chem. 282, 30910-30919 (Pubitemid 350035181)
28. Hastak, K., Gupta, S., Ahmad, N., Agarwal, M. K., Agarwal, M. L., and Mukhtar, H. (2003) Role of p53 and NF-kappaB in epigallocatechin-3-gallate- induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859 (Pubitemid 36981273)
29. Hsu, C. L., Chen, Y. L., Ting, H. J., Lin, W. J., Yang, Z., Zhang, Y., Wang, L., Wu, C. T., Chang, H. C., Yeh, S., Pimplikar, S. W., and Chang, C. (2005) Androgen receptor (AR) NH2-and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol. Endocrinol. 19, 350-361 (Pubitemid 40223460)
30. Wong, C. I., Zhou, Z. X., Sar, M., and Wilson, E. M. (1993) Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J. Biol. Chem. 268, 19004-19012 (Pubitemid 23273853)
31. Zhou, Z. X., Lane, M. V., Kemppainen, J. A., French, F. S., and Wilson, E. M. (1995) Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol. Endocrinol. 9, 208-218
32. Khan, N., Asim, M., Afaq, F., Abu Zaid, M., and Mukhtar, H. (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 68, 8555-8563
33. Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., Demayo, F. J., Tilley, W., and Greenberg, N. M. (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U. S. A. 102, 1151-1156 (Pubitemid 40170741)
34. Hyytinen, E. R., Haapala, K., Thompson, J., Lappalainen, I., Roiha, M., Rantala, I., Helin, H. J., Janne, O. A., Vihinen, M., Palvimo, J. J., and Koivisto, P. A. (2002) 1Pattern of somatic androgen receptor gene mutations in patients with hormonerefractory prostate cancer. Lab. Invest. 82, 1591-1598 (Pubitemid 35332918)
35. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 12511-2515
36. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., and Tindall, D. J. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477
37. Centenera, M. M., Harris, J. M., Tilley, W. D., and Butler, L. M. (2008) The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 22, 2373-2382
38. Lee, D. K., and Chang, C. (2003) Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J. Clin. Endocrinol. Metab. 88, 4043-4054 (Pubitemid 37153696)
39. Ambs, S., Prueitt, R. L., Yi, M., Hudson, R. S., Howe, T. M., Petrocca, F., Wallace, T. A., Liu, C. G., Volinia, S., Calin, G. A., Yfantis, H. G., Stephens, R. M., and Croce, C. M. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162-6170
40. Ozen, M., Creighton, C. J., Ozdemir, M., and Ittmann, M. (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793 (Pubitemid 351380263)
41. Porkka, K. P., Pfeiffer, M. J., Waltering, K. K., Vessella, R. L., Tammela, T. L., and Visakorpi, T. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res. 67, 6130-6135 (Pubitemid 47037493)
42. Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., Mendell, J. T., and Lupold, S. E. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 69, 17165-7169
43. Lee, K. H., Chen, Y. L., Yeh, S. D., Hsiao, M., Lin, J. T., Goan, Y. G., and Lu, P. J. (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28, 3360-3370
44. Zhu, W., Zhu, D. S., Madan, R. A., Gulley, J. L., Figg, W. D., and Dahut, W. L. (2009) Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am. J. Ther. 17, 176-181.
45. Chen, Y., Sawyers, C. L., and Scher, H. I. (2008) Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 8, 440-448
46. Brusselmans, K., De Schrijver, E., Heyns, W., Verhoeven, G., and Swinnen, J. V. (2003) Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int. J. Cancer 106, 856-862 (Pubitemid 37071663)
47. Stuart, E. C., Scandlyn, M. J., and Rosengren, R. J. (2006) Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci. 79, 2329-2336 (Pubitemid 44772933)
48. Blot, W. J., Chow, W. H., and McLaughlin, J. K. (1996) Tea and cancer: a review of the epidemiological evidence. Eur. J. Cancer Prev. 5, 425-438 (Pubitemid 27087365)
49. Liao, S., and Hiipakka, R. A. (1995) Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3- gallate. Biochem. Biophys. Res. Commun. 214, 833-838
50. Paschka, A. G., Butler, R., and Young, C. Y. (1998) Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. 130, 1-7 (Pubitemid 28425331)
51. Ahmad, N., Feyes, D. K., Nieminen, A. L., Agarwal, R., and Mukhtar, H. (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 89, 1881-1886 (Pubitemid 28009824)
52. Gupta, S., Ahmad, N., Mohan, R. R., Husain, M. M., and Mukhtar, H. (1999) Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res. 59, 2115-2120 (Pubitemid 29217674)
53. Gupta, S., Ahmad, N., Nieminen, A. L., and Mukhtar, H. (2000) Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol. Appl. Pharmacol. 164, 82-90 (Pubitemid 30198547)
54. Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., and Balk, S. P. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321-26326 (Pubitemid 34967123)
55. Brinkmann, A. O., Blok, L. J., de Ruiter, P. E., Doesburg, P., Steketee, K., Berrevoets, C. A., and Trapman, J. (1999) Mechanisms of androgen receptor activation and function. J. Steroid. Biochem. Mol. Biol. 69, 307-313 (Pubitemid 29305551)
56. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285 (Pubitemid 29124362)
57. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843 (Pubitemid 40839736)